The April 2026 Department of Justice order immediately moved FDA-approved marijuana products and those covered by state medical licenses into Schedule III of the Controlled Substances Act, while terminating prior proceedings and launching a new expedited DEA administrative hearing on June 29, 2026, to evaluate broader rescheduling of all marijuana. This follows a December 2025 executive order directing faster action on the long-pending proposal first advanced in 2024. Traders are weighing the compressed hearing timeline ending no later than July 15 against the remaining rulemaking steps, potential legal challenges, and agency processing requirements before a final rule can take effect. The outcome hinges on whether these procedural milestones are completed in 2026 or face extensions.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया$758,623 वॉल्यूम
31 मार्च, 2026
30 जून
1%
31 दिसंबर
24%
$758,623 वॉल्यूम
30 जून
$337,166 वॉल्यूम
1%
31 दिसंबर
$156,575 वॉल्यूम
24%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order immediately moved FDA-approved marijuana products and those covered by state medical licenses into Schedule III of the Controlled Substances Act, while terminating prior proceedings and launching a new expedited DEA administrative hearing on June 29, 2026, to evaluate broader rescheduling of all marijuana. This follows a December 2025 executive order directing faster action on the long-pending proposal first advanced in 2024. Traders are weighing the compressed hearing timeline ending no later than July 15 against the remaining rulemaking steps, potential legal challenges, and agency processing requirements before a final rule can take effect. The outcome hinges on whether these procedural milestones are completed in 2026 or face extensions.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
बाज़ार खुला: Feb 7, 2026, 5:04 PM ET
वॉल्यूम
$758,623समाप्ति तिथि
31 मार्च, 2026बाज़ार खुला
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order immediately moved FDA-approved marijuana products and those covered by state medical licenses into Schedule III of the Controlled Substances Act, while terminating prior proceedings and launching a new expedited DEA administrative hearing on June 29, 2026, to evaluate broader rescheduling of all marijuana. This follows a December 2025 executive order directing faster action on the long-pending proposal first advanced in 2024. Traders are weighing the compressed hearing timeline ending no later than July 15 against the remaining rulemaking steps, potential legal challenges, and agency processing requirements before a final rule can take effect. The outcome hinges on whether these procedural milestones are completed in 2026 or face extensions.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
वॉल्यूम
$758,623समाप्ति तिथि
31 मार्च, 2026बाज़ार खुला
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The April 2026 Department of Justice order immediately moved FDA-approved marijuana products and those covered by state medical licenses into Schedule III of the Controlled Substances Act, while terminating prior proceedings and launching a new expedited DEA administrative hearing on June 29, 2026, to evaluate broader rescheduling of all marijuana. This follows a December 2025 executive order directing faster action on the long-pending proposal first advanced in 2024. Traders are weighing the compressed hearing timeline ending no later than July 15 against the remaining rulemaking steps, potential legal challenges, and agency processing requirements before a final rule can take effect. The outcome hinges on whether these procedural milestones are completed in 2026 or face extensions.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न